Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974004 | 0.91 | ECE1 (0.41) | SMN1; SMN2RAB9AMAPTRXFP1F10 | |
| SCHEMBL975637 | 0.84 | F10 (0.43) | SMN1; SMN2RAB9AMAPTF10ECE1 | |
| SCHEMBL977067 | 0.84 | ECE1 (0.46) | F10ECE1MAOBCCR2 | |
| SCHEMBL973562 | 0.82 | ECE1 (0.46) | MAPTF10ECE1MAOBNPSR1 | |
| SCHEMBL975282 | 0.81 | F10 (0.46) | RAB9AMAPTF10ECE1L3MBTL1 | |
| SCHEMBL975450 | 0.80 | KDM4E (0.46) | SMN1; SMN2MAPTF10ECE1L3MBTL1 | |
| SCHEMBL974090 | 0.77 | PPARG (0.43) | ECE1CCR2 | |
| SCHEMBL975576 | 0.77 | ECE1 (0.47) | F10ECE1MAOBCCR2 | |
| SCHEMBL832765 | 0.76 | ECE1 (0.44) | SMN1; SMN2MAPTF10ECE1TP53 | |
| SCHEMBL975228 | 0.74 | F10 (0.48) | F10ECE1MAOBCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235016-B1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-09-18 | — | — | EP | claimed |
| US-20110009444-A1 | N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| EP-2235016-B1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-8394820-B2 | N-azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-03-12 | — | — | US | disclosed |
| US-20110009444-A1 | N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009444-A1 | N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, NQO2, SLC28A2 | SMN1; SMN2 1410/4885RAB9A 2026/4885MAPT 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.